4-[5,6-Dichloro-1-(2-iodo-ethyl)-1H-benzoimidazol-2-yl]-piperidine-1-carboxylic acid tert-butyl ester | 578708-38-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 4-[5,6-Dichloro-1-(2-iodo-ethyl)-1H-benzoimidazol-2-yl]-piperidine-1-carboxylic acid tert-butyl ester
• CAS: 578708-38-0
• 化学式: C₁₉H₂₄Cl₂IN₃O₂
• 分子量: 524.229
• InChiKey: LCAPDQQHEAIPCI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.89
• 重原子数：
  27.0
• 可旋转键数：
  3.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  47.36
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  4-[5,6-Dichloro-1-(2-iodo-ethyl)-1H-benzoimidazol-2-yl]-piperidine-1-carboxylic acid tert-butyl ester 在 盐酸 、 sodium hydride 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 0.5h， 生成 2-[2-(5,6-Dichloro-2-piperidin-4-yl-benzoimidazol-1-yl)-ethyl]-isoindole-1,3-dione
  参考文献：
  名称：

  Synthesis and biological evaluations of novel benzimidazoles as potential antibacterial agents

  摘要：

  A series of novel benzimidazole derivatives were synthesized via parallel solution-phase chemistry. Many of these compounds were found to inhibit the growth of Staphylococcus aureus and Escherichia coli. Several analogues exhibited low micromolar minimal inhibitory concentrations (MIC) against both Gram-positive and Gram-negative bacteria of clinical relevance and could serve as leads for further optimizations for antibacterial research. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.12.051
• 作为产物：
  描述：

  1-Boc-4-哌啶甲酸 在 4-二甲氨基吡啶 、 sodium hydroxide 、 sodium hydride 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 生成 4-[5,6-Dichloro-1-(2-iodo-ethyl)-1H-benzoimidazol-2-yl]-piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Synthesis and biological evaluations of novel benzimidazoles as potential antibacterial agents

  摘要：

  A series of novel benzimidazole derivatives were synthesized via parallel solution-phase chemistry. Many of these compounds were found to inhibit the growth of Staphylococcus aureus and Escherichia coli. Several analogues exhibited low micromolar minimal inhibitory concentrations (MIC) against both Gram-positive and Gram-negative bacteria of clinical relevance and could serve as leads for further optimizations for antibacterial research. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.12.051